Trials / Terminated
TerminatedNCT00662116
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Synvista Therapeutics, Inc · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to evaluate the safety and effectiveness of alagebrium in subjects diagnosed with diastolic heart failure. The primary assessment for effectiveness is the assessment of exercise tolerance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alagebrium | 200 mg (two 100 mg tablets) two times daily for 24 weeks |
| DRUG | placebo | placebo tablets - two tablets taken twice daily |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-10-01
- Completion
- 2009-12-01
- First posted
- 2008-04-21
- Last updated
- 2009-01-30
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00662116. Inclusion in this directory is not an endorsement.